secwatch / observer
TPST Tempest Therapeutics, Inc.
CIK 0001544227 50 ready 8-Ks latest August 13, 2026, 4:36 PM ET RSS · JSON
Activity: ELEVATED 4 filings / 30d vs 2 baseline Risk accumulating: repeated leadership change (12)
Ready 8-Ks 50
Latest filing August 24, 2026, 4:43 PM ET
Top materiality 0.95
Event mix other_material ×23 · earnings ×13 · leadership ×6
Sentiment 14 pos · 7 neg · 29 neu
Latest earnings reported 2025-Q3
Executive change recent →
SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for TPST

Highest-materiality recent filing

Tempest closes CAR T asset acquisition from Erigen; Erigen owns 61.3% post-closing

February 6, 2026, 6:59 PM ET M&A materiality 0.95 neutral item 1.01item 2.01item 3.02item 5.01item 5.02item 9.01 ◈ Equity Issuances ×2◈ M&A Transactions

Read filing →

Executive changes

Departed

Justin Trojanowski

Principal Financial Officer and Principal Accounting Officer
TPST · Tempest Therapeutics, Inc.
Effective
2026-09-01
Successor
Nicholas Rossettos
Filed
August 24, 2026, 4:43 PM ET
On August 18, 2026, Mr. Justin Trojanowski notified Tempest Therapeutics, Inc. (the “Company”) of his decision to resign from his positions as Principal Financial Officer and Principal Accounting Officer of the Company, and from any and all other positions he holds with the Company, effective as of September 1, 2026.
Appointed

Nicholas Rossettos

Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary
TPST · Tempest Therapeutics, Inc.
Effective
2026-09-01
Filed
August 24, 2026, 4:43 PM ET
Effective September 1, 2026, the Board of Directors of the Company (the “Board”) appointed Mr. Nicholas Rossettos as Chief Financial Officer Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary of the Company.
Appointed

John David Yee

Class II Director
TPST · Tempest Therapeutics, Inc.
Effective
2026-06-04
Filed
June 4, 2026, 5:00 PM ET
the Board appointed Dr. John David Yee and Mr. William Drake Richey as Class II directors to fill vacancies on the Board.
Appointed

Justin Trojanowski

Vice President, Finance, Principal Financial Officer and Corporate Secretary
TPST · Tempest Therapeutics, Inc.
Effective
2026-06-05
Filed
June 4, 2026, 5:00 PM ET
the Board of Directors of the Company (the “Board”) appointed Mr. Justin Trojanowski as Vice President, Finance, Principal Financial Officer and Corporate Secretary of the Company, in addition to his current role as Corporate Controller, Treasurer and Principal Accounting Officer of the Company.
Appointed

William Drake Richey

Class II Director
TPST · Tempest Therapeutics, Inc.
Effective
2026-06-04
Filed
June 4, 2026, 5:00 PM ET
the Board appointed Dr. John David Yee and Mr. William Drake Richey as Class II directors to fill vacancies on the Board.
Departed

Nicholas Maestas

Chief Financial Officer
TPST · Tempest Therapeutics, Inc.
Effective
2026-06-05
Successor
Justin Trojanowski
Filed
June 4, 2026, 5:00 PM ET
Mr. Nicholas Maestas notified Tempest Therapeutics, Inc. (the “Company”) of his decision to resign from his position as Chief Financial Officer of the Company and from any and all other positions he holds with the Company, effective as of June 5, 2026.
Departed

Simantov

Director
TPST · Tempest Therapeutics, Inc.
Effective
2026-05-23
Filed
May 29, 2026, 5:01 PM ET
On May 23, 2026, Ms. Simantov notified Tempest Therapeutics, Inc. (the "Company") of her resignation from the Board of Directors of the Company (the "Board"), effective as of such date.
Departed

Christine Pellizzari

Director
TPST · Tempest Therapeutics, Inc.
Filed
May 22, 2026, 5:28 PM ET
resignations of Mr. Michael Raab and Ms. Christine Pellizzari from the Board
Departed

Michael Raab

Director
TPST · Tempest Therapeutics, Inc.
Filed
May 22, 2026, 5:28 PM ET
resignations of Mr. Michael Raab and Ms. Christine Pellizzari from the Board
Departed

Christine Pellizzari

Director
TPST · Tempest Therapeutics, Inc.
Effective
2026-05-22
Filed
May 22, 2026, 5:05 PM ET
On May 22, 2026, each of Mr. Stephen Brady, Mr. Michael Raab and Ms. Christine Pellizzari notified Tempest Therapeutics, Inc. (the “Company”) of his or her resignation from the Board of Directors of the Company (the “Board”), effective as of such date.
Departed

Michael Raab

Director
TPST · Tempest Therapeutics, Inc.
Effective
2026-05-22
Filed
May 22, 2026, 5:05 PM ET
On May 22, 2026, each of Mr. Stephen Brady, Mr. Michael Raab and Ms. Christine Pellizzari notified Tempest Therapeutics, Inc. (the “Company”) of his or her resignation from the Board of Directors of the Company (the “Board”), effective as of such date.
Departed

Stephen Brady

Director
TPST · Tempest Therapeutics, Inc.
Effective
2026-05-22
Filed
May 22, 2026, 5:05 PM ET
On May 22, 2026, each of Mr. Stephen Brady, Mr. Michael Raab and Ms. Christine Pellizzari notified Tempest Therapeutics, Inc. (the “Company”) of his or her resignation from the Board of Directors of the Company (the “Board”), effective as of such date.

Earnings & guidance

2025-Q3 EPS reported -$5.71 filing →

Materiality & sentiment trend

Max materiality 0.95 · Median 0.65 · Most common event other_material

14 positive 7 negative 29 neutral

source · TPST on sec.gov